



OPEN ACCESS

Research article

Frequency of lipoprotein(a) testing and its levels in Pakistani population

Hijab Batool¹, Madeeha Khan^{2,3}, Quratul Ain^{2,4}, Omar R. Chughtai¹, Muhammad D. Khan¹, Mohammad I. Khan^{5,6}, Fouzia Sadiq^{2*}

ABSTRACT

Background: Lipoprotein(a) [Lp(a)] is a highly atherogenic particle identified as an independent risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). This study aimed to investigate the frequency of Lp(a) testing and the incidence of elevated Lp(a) levels in the Pakistani population.

Methods: For this observational study, Lp(a) and lipid profile data from five years (June 2015 to October 2020) were acquired from the electronic patient records of a diagnostic laboratory with a countrywide network. The association of age and total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL, and triglyceride (TG) levels with two thresholds for Lp(a), that is, <30 mg/dL and ≥ 30 mg/dL, was calculated using the Kruskal-Wallis test, while the association between Lp(a) levels and lipid variables was calculated using Spearman correlation.

Results: For five years, 1060 tests were conducted, averaging 212 tests per year. Of these, 37.2% showed Lp(a) levels above 30 mg/dL. No significant differences were observed in the results between males and females. However, younger individuals displayed significantly higher Lp(a) levels. Additionally, there was only a weak correlation between the Lp(a) levels and other lipid variables.

Conclusion: Despite being recognized as a risk factor for ASCVD in the Pakistani population, only a small proportion of the large population underwent Lp(a) testing. Moreover, a significant proportion of the population exceeded this threshold.

¹ Chemical Pathology, Chughtai Institute of Pathology, Lahore, Pakistan

² Directorate of Research, Shifa Tameer-e-Millat University, Pitras Bukhari Road, H-8/4, Islamabad 44000, Pakistan

³ Atta ur Rehman School of Applied Biosciences, National University of Sciences and Technology, H-12, Islamabad 44000, Pakistan

⁴ Translational Genomics Laboratory, Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan

⁵ Shifa Tameer-e-Millat University, Pitras Bukhari Road, H-8/4, Islamabad 44000, Pakistan

⁶ Department of Vascular Surgery, Shifa International Hospital Pitras Bukhari Road, H-8/4, Islamabad 44000, Pakistan

*Email: director.research@stmu.edu.pk

<https://doi.org/10.21542/gcsp.2024.37>

Received: 19 March 2024

Accepted: 23 July 2024

© 2024 The Author(s), licensee Magdi Yacoub Institute. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Batool H, Khan M, Ain Q, Chughtai OR, Khan MD, Khan MI, Sadiq F. Frequency of lipoprotein(a) testing and its levels in Pakistani population, Global Cardiology Science and Practice 2024;37 <https://doi.org/10.21542/gcsp.2024.37>

INTRODUCTION

Lipoprotein(a) [Lp(a)] is a macromolecular structure comprising a lipid core of cholesterol esters and triacylglycerols surrounded by an outer shell of phospholipids, free cholesterol, and apolipoprotein B-100 (apoB-100) particles linked to apolipoprotein a [apo(a)] glycoprotein^{1,2}. Lp(a) is synthesized exclusively in hepatocytes and is a major carrier of oxidized phospholipids (OxPLs) that can trigger multiple pro-inflammatory pathways^{3,4}. Circulating levels of Lp(a) are determined by the *LPA* gene locus and are not influenced by dietary or environmental factors⁵. Data from randomized control trials have shown that diets lower in saturated fats, hormone replacement therapy (HRT), and liver disease result in lowered Lp(a) levels, whereas kidney disease results in a marked elevation of Lp(a)⁶.

Evidence from several studies suggests that elevated Lp(a) level is an independent risk factor for the development of ASCVD, including aortic valve stenosis, coronary heart disease, myocardial infarction, and stroke^{7–12}. Several international guidelines have included Lp(a) testing in their recommendations, particularly for individuals with a high risk of cardiovascular diseases^{13–19}. Plasma Lp(a) levels are genetically determined and generally remain stable; however, genetic variability exists among different ethnic groups, with greater levels observed in Africans than in Caucasians, Hispanics, and Asian populations^{20,21}. Generally, an Lp(a) concentration of 50 mg/dL is considered a high-risk threshold²². High Lp(a) levels (>50 mg/dL) are estimated to be prevalent in 20% of the population worldwide⁵. Elevated Lp(a) levels have been identified as a causal risk factor in the Pakistani population; however, Lp(a) testing is not considered in routine ASCVD diagnosis^{23,24}.

This study aimed to investigate the incidence of Lp(a) testing and elevated Lp(a) levels in a Pakistani population.

METHODS

Study population

For this retrospective study, anonymized Lp(a) data from individuals referred for lipid testing between June 2015 and October 2020 were acquired from the electronic patient records of a diagnostic laboratory operating collection centers throughout Pakistan.

Lp(a) and lipid profile analysis

Lp(a) levels were measured using an immunoturbidimetric assay (Alinity c Lp(a) kit, Abbott Laboratories, Illinois, USA). The lipid profile data for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL), total cholesterol (TC), and triglycerides (TG) were measured using a homogenous assay (Abbott Alinity CI analyzer).

Statistical analysis

The data for study variables, including age, Lp(a), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), non-HDL, and triglyceride (TG) levels, were reported using descriptive statistics (minimum, maximum, median, and interquartile range [IQR]). The association between Lp(a) levels and sex was calculated using the Mann–Whitney U test. The level of significance was set at $p < 0.05$. Kruskal-Wallis tests were used to evaluate differences in Lp(a) levels among age groups and to analyze the association between age and lipid parameters (TC, HDL, LDL, non-HDL, and TG) with

Table 1 Data variables of the study.

Data characteristics	Minimum	Maximum	Median	IQR
Age ($n = 1060$)	3.0	98.0	47.0	37.0–58.0
Lp(a) ($n = 1060$)	1.3	281.3	20.7	9.8–43.8
TC mg/dL ($n = 190$)	104.0	1010.0	192.0	156.7–222.5
HDL-C mg/dL ($n = 190$)	18.0	86.0	39.0	32.0–46.2
LDL-C mg/dL ($n = 190$)	50.0	800.0	123.0	94.7–162.2
Non-HDL mg/dL ($n = 190$)	62.0	990.0	149.5	114.7–184.2
TG mg/dL ($n = 190$)	38.0	891.0	134.5	97.0–215.0
Lp (a) ($n = 190$) [*]	1.3	281.3	19.2	9.2–47.4
Age ($n = 190$) [*]	3.0	83.0	41.5	30.7–52.0

Notes.

IQR, Interquartile range; Lp (a), Lipoprotein (a); TC, Total cholesterol; TG, Triglycerides; HDL-C, High-density lipoprotein cholesterol.

^{*}Lp(a) levels and age data were gathered from 190 patients who had complete lipid profiles out of a larger group of 1060 patients with Lp(a) data.

two Lp(a) thresholds (<30 mg/dL and ≥ 30 mg/dL). All statistical analyses and data visualizations were performed using SPSS version 27.

RESULTS

In total, 1,060 individuals were included in this study. Lipid profiles were measured in 190 patients. Details of the study variables, such as age, Lp(a), TC, HDL, LDL, non-HDL, and TG, are presented in Table 1. The median age of participants was 47 years. The median Lp(a) level was 20.75 (9.8–43.85) mg/dL. Among these, 37.5% ($n = 395$) had Lp(a) levels > 30 mg/dL, while 21.3% ($n = 225$) had Lp(a) levels > 50 mg/dL. The data for lipid variables were available for 190 individuals, including the median levels of TC, HDL, LDL, and non-HDL. was obtained (Table 1).

The levels of Lp(a) were not significantly different between sexes ($p = 0.45$). Figure 1 shows the frequency distribution of Lp(a) levels in both male and female participants. The levels of Lp(a) were compared across various age groups, including those under 20 years, between 20 and 40 years, between 40 and 60 years, and over 60 years. The results showed significant differences between the groups ($p = 0.03$) (Table 2). The median Lp(a) level for those ages below 20 years was 31.2 (9.1–92.2) mg/dL, while 23.3





Figure 1. Gender-based Lp(a) frequency distribution in the Pakistani population, a) females, b) males.

Table 2 Association of gender and age with lipoprotein (a) levels.

Data variables	N (%)	95% CI (Q1-Q3)	Lp(a) levels Median (IQR)	p value
Gender	Male	696.0 (76.0)	30.1–35.2	0.45
	Female	364.0 (34.0)	30.2–37.6	
Age (years)	<20	43.0 (4.0)	36.6–73.6	0.03
	20–40	287.0 (27.0)	25.8–33.3	
	40–60	501.0 (47.0)	29.1–34.7	
	>60	229.0 (22.0)	31.1–40.5	

Notes.

IQR, Interquartile range; CI, Confidence Interval.

**Figure 2. Trends of Lp(a) levels in different age groups of males and females.**

(10.2–47.6) mg/dL for those aged above 60 years. Higher Lp(a) levels were observed in the younger population aged less than 20 years (Figure 2). Significant differences were observed for TC, LDL, and TG when comparing the association of the study variables among the thresholds of Lp(a). No association was found between age, HDL or non-HDL levels, and Lp(a) thresholds (Figure 3, Table 3).

DISCUSSION


This study presents the levels and incidence of Lp(a) testing in Pakistan. The results show that only 1060 tests were performed over five years. Among those tested, 21.2% had Lp(a) levels above 50 mg/dL, which is identified as a risk threshold based on the European Atherosclerosis Society/European Society of Cardiology (EAS/ESC) guidelines, while 37.2% had Lp(a) levels above 30 mg/dL, which is categorized as a risk category according to the American Heart Association (AHA) guidelines^{14,16}. The median Lp(a) level of individuals included in the present study was 20.75 mg/dL. Previously, for Pakistani population higher mean levels were observed for those with acute coronary syndrome (47.03 mg/dL, $n = 90$) and diabetes (47.65 mg/dL, $n = 68$)^{25,26}. Plasma Lp(a) concentration vary considerably among different racial and ethnic groups, where individuals of African ancestry have the highest levels while East Asians tend to have the lowest levels, while South Asians, Whites and Hispanics have intermediate levels^{22,27,28}. These differences can be attributed to kringle IV polymorphisms in the *LPA* gene that code for apo(a), leading to wide variability in Lp(a) size within the population and among

Table 3 Association of age, TC, HDL, LDL, non-HDL, and TG with Lp(a) thresholds i.e., <30 mg/dL and ≥ 30 mg/dL.

<i>N</i> = 190	Lp(a) <30 mg/dL (<i>n</i> = 119)		Lp(a) ≥ 30 mg/dL (<i>n</i> = 71)		p value
	Median	IQR (Q1-Q3)	Median	IQR (Q1-Q3)	
Age (Years)	42.0	31.0–52.0	40.0	30.0–51.0	0.75
TC (mg/dL)	183.0	150.0–216.0	204.0	172.0–239.0	0.01
HDL-C (mg/dL)	38.0	32.0–45.0	42.0	32.0–48.0	0.10
LDL-C (mg/dL)	114.0	93.0–152.0	135.0	103.0–174.0	0.01
Non-HDL (mg/dL)	147.0	112.0–181.0	159.0	124.0–194.0	0.07
TG (mg/dL)	142.0	102.0–242.0	115.0	92.0–179.0	0.02

Notes.

IQR, Interquartile range; TC, Total cholesterol; TG, Triglycerides; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol.

**Figure 3.** Spearman correlation between Lp(a), age, and lipid variables.

different ethnic groups²⁹. In the present study, slightly higher levels were observed in the study population, compared to those observed in the Southeast Asian population (Figure 4)³⁰. As the data were obtained from a referral laboratory, this might explain the slightly higher levels.

The results of the present study show that Lp(a) levels were significantly higher in younger individuals than in those aged 60 years or above. Similar results were observed in a study conducted in a multi-ethnic population with a history of ASCVD³¹. Since elevated Lp(a) levels result in premature ASCVD, this could be the reason for higher Lp(a) observed in younger population. Moreover, the levels of Lp(a) were weakly correlated with other lipid variables such as TC, HDL, LDL-C, and TG. Previous studies have shown a weak correlation between Lp(a) levels and other lipid variables^{32,33}.

However, higher Lp(a) levels were observed with higher LDL-C levels. A similar relationship was demonstrated in previous studies³⁴. Triglyceride levels were negatively correlated with Lp(a) levels which is consistent with the results of other studies^{32,35}. This could be either due to binding of apo(a) to the apoB of VLDL particles during the VLDL synthesis leading to the synthesis of VLDL-like particles that can be further metabolized




Figure 4. Median Lp(a) median values reported in the present study compared to the levels reported in other ethnicities.

by lipolysis or this could be due to Lp(a) metabolism by enzymes involved in TG and VLDL metabolism^{36–38}.

Specific Lp(a) lowering therapies are not available yet and are still in clinical trials³⁹. Statins remain the first line of lipid lowering therapy however, statins can significantly increase plasma Lp(a) levels^{40,41}. Other drugs including proprotein convertase subtilase/kexin type 9 inhibitors (PCSK9i) and mipomersen have the potential to lower Lp(a) levels^{42,43}. The emerging mRNA therapies have also shown their effectiveness to lower Lp(a) levels in clinical trials^{44–46}. Due to the nature of the present study, the data on lipid lowering drugs is not available, therefore this aspect could not be addressed in the present study.

Several international guidelines recommend Lp(a) measurement at least once in the lifetime of an individual, however Lp(a) testing is not highly adopted worldwide and heterogeneity regarding the incorporation of Lp(a) testing in patient care still exists^{47–50}. In Pakistan, where cardiovascular diseases remain the leading cause of deaths, early screening of risk factors in the population can help prevent cardiovascular events. Since, Lp(a) remains an independent causal factor for ASCVD, it is imperative that Lp(a) testing is conducted at a large scale. It is evident from the present study, only a fraction of population had their Lp(a) levels tested, therefore measures should be taken to ensure Lp(a) testing at least once preferably with the first lipid profile. This will not only aid physicians to stratify the risk of cardiovascular events but will also be helpful in reducing the burden of cardiovascular diseases.

There are some limitations of the present study. The major one is that since the data was obtained from a referral laboratory, details of the disease status such as presence of ASCVD, diabetes, kidney or liver disease of the individuals were not available, therefore the risk and impact of these conditions on Lp(a) levels cannot be ascertained. Moreover, the study presents a cohort referred for Lp(a) testing which could have introduced a selection bias limiting the generalizability of our findings. As mentioned earlier, due to the nature of the data utilized for this study, the details of the medications and their impact on Lp(a) levels could not be elucidated.

CONCLUSION

The present study showed that only a small fraction of the population of Pakistan is registered for Lp(a) testing. A significant proportion of our study population had Lp(a) levels above the suggested threshold. Being a country with the highest rate of mortality

due to cardiovascular diseases, it is imperative to screen the general population for ASCVD risk stratification, and the inclusion of mandatory Lp(a) testing can be helpful in early screening. There is a dire need for education regarding the recommended guidelines for Lp(a) testing and the appropriate clinical management of patients with elevated Lp(a) levels. Additionally, public health policies should be developed and implemented to address this issue, focusing on increasing awareness, improving screening practices, and ensuring access to appropriate interventions

AUTHORS' CONTRIBUTIONS

Conceptualization: Fouzia Sadiq. **Methodology:** Hijab Batool, Omar R. Chughtai, and Muhammad D. Khan. **Resources:** Hijab Batool, Quratul Ain, Omar R. Chughtai, and Muhammad D. Khan. **Supervision:** Mohammad I. Khan and Fouzia Sadiq. **Validation:** Hijab Batool. **Visualization:** Madeeha Khan and Quratul Ain. **Writing - original draft:** Hijab Batool, Madeeha Khan, and Quratul Ain. **Writing - review & editing:** Hijab Batool, Madeeha Khan, Quratul Ain, Omar R. Chughtai, Muhammad D. Khan, Mohammad I. Khan, and Fouzia Sadiq.

ACKNOWLEDGEMENT

We are thankful to Mr. Amjad Nawaz, Shifa Tameer e Millat University, Islamabad, for helping in conducting statistical analysis.

REFERENCES

- [1] Gaubatz JW, Heideman C, Gotto Jr AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]. Structural properties. *Journal of Biological Chemistry*. 1983;258(7):4582–4589. doi: [10.1016/S0021-9258\(18\)32663-2](https://doi.org/10.1016/S0021-9258(18)32663-2).
- [2] Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: A new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. Jiang X.C. ed. *J Lipids*. 2020;2020:3491764 doi: [10.1155/2020/3491764](https://doi.org/10.1155/2020/3491764).
- [3] Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). *J Lipid Res*. 2016;57(8):1339–1359. doi: [10.1194/jlr.R067314](https://doi.org/10.1194/jlr.R067314).
- [4] McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature*. 1987;330(6144):132–137. doi: [10.1038/330132a0](https://doi.org/10.1038/330132a0).
- [5] Tsimikas S. A test in context: lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol*. 2017;69(6):692–711. doi: <https://doi.org/10.1016/j.jacc.2016.11.042>.
- [6] Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. *Atherosclerosis*. 2022;349:53–62. doi: <https://doi.org/10.1016/j.atherosclerosis.2022.04.006>.
- [7] Bhatia HS, Ma GS, Taleb A, Wilkinson M, Kahn AM, Cotter B, Yeang C, De Maria AN, Patel MP, Mahmud E, Reeves RR, Tsimikas S. Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. *Atherosclerosis*. 2022;349:144–150. doi: [10.1016/j.atherosclerosis.2022.01.022](https://doi.org/10.1016/j.atherosclerosis.2022.01.022).
- [8] Zhu L, Zheng J, Gao B, Jin X, He Y, Zhou L, Huang J. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels. *BMC Cardiovasc Disord*. 2022;22(1):1–10. doi: [10.1186/S12872-022-02618-5/TABLES/4](https://doi.org/10.1186/S12872-022-02618-5/TABLES/4).
- [9] Cao J, Steffen BT, Budoff M, Post WS, Thanassoulis G, Kestenbaum B, Mcconnell JP, Warnick R, Guan W, Tsai MY. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: The multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2016;36(5):1003–1009. doi: [10.1161/ATVBAHA.115.306683](https://doi.org/10.1161/ATVBAHA.115.306683).
- [10] Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. 2009;361(26):2518–2528. doi: [10.1056/NEJMOA0902604](https://doi.org/10.1056/NEJMOA0902604).
- [11] Arora P, Kalra R, Callas PW, Alexander KS, Zakai NA, Wadley V, Arora G, Kissela BM, Judd SE, Cushman M. Lipoprotein(a) and risk of ischemic stroke in the REGARDs study. *Arterioscler Thromb Vasc Biol*. 2019;39(4):810–818. doi: [10.1161/ATVBAHA.118.311857](https://doi.org/10.1161/ATVBAHA.118.311857).
- [12] Kumar P, Swarnkar P, Misra S, Nath M. Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis. *Scientific Reports*. 2021;11(1):1–13. doi: [10.1038/s41598-021-95141-0](https://doi.org/10.1038/s41598-021-95141-0).

- [13] Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, Datta D, Capps N, Shoulders C, Qureshi N, Rees A, Main L, Cramb R, Viljoen A, Payne J, Soran H. HEART UK consensus statement on Lipoprotein(a): A call to action. *Atherosclerosis*. 2019;291:62–70. doi: [10.1016/j.atherosclerosis.2019.10.011](https://doi.org/10.1016/j.atherosclerosis.2019.10.011).
- [14] Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;73(24):e285–e350. doi: [10.1016/j.jacc.2018.11.003](https://doi.org/10.1016/j.jacc.2018.11.003).
- [15] Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm –2020 executive summary. *Endocrine Practice*. 2020;26(10):1196–1224. doi: [10.4158/CS-2020-0490](https://doi.org/10.4158/CS-2020-0490).
- [16] Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, Mueller C, Drexel H, Aboyans V, Corsini A, Doehner W, Farnier M, Gigante B, Kayikcioglu M, Krstacic G, Lambrinou E, Lewis BS, Masip J, Moulin P, Petersen S, Petronio AS, Piepoli MF, Pinto X, Raber L, Ray KK, Reiner Z, Riesen WF, Roffi M, Schmid JP, Shlyakhto E, Simpson IA, Stroes E, Sudano I, Tselepis AD, Viigimaa M, Vindis C, Vonbank A, Vrablik M, Vrsalovic M, Gomez JLZ, Collet JP, Windecker S, Dean V, Fitzsimons D, Gale CP, Grobbee DE, Halvorsen S, Hindricks G, Jung B, Juni P, Katus HA, Leclercq C, Lettino M, Merkely B, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafavov R, Van De Borne P, Pojskic B, Postadzhiyan A, Kypris L, Spinar J, Larsen ML, Eldin HS, Strandberg TE, Ferrières J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudjonsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, et al. ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2019;41(1):111–188. doi: [10.1093/eurheartj/ehz455](https://doi.org/10.1093/eurheartj/ehz455).
- [17] Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Canadian Journal of Cardiology*. 2021;37(8):1129–1150. doi: [10.1016/j.cjca.2021.03.016](https://doi.org/10.1016/j.cjca.2021.03.016).
- [18] Stefanutti C, Julius U, Watts GF, Harada-Shiba M, Cossu M, Schettler VJ, De Silvestro G, Soran H, Van Lennep JR, Pisciotta L, Klör HU, Widhalm K, Moriarty PM, D'Alessandri G, Bianciardi G, Bosco G, De Fusco G, Di Giacomo S, Morozzi C, Mesce D, Vitale M, Sovrano B, Drogari E, Ewald N, Gualdi G, Jaeger BR, Lanti A, Marson P, Martino F, Migliori G, Parasassi T, Pavan A, Perla FM, Brunelli R, Perrone G, Renga S, Ries W, Romano N, Romeo S, Pergolini M, Labbadia G, Di Iorio B, De Palo T, Abbate R, Marcucci R, Poli L, Ardissino G, Ottone P, Tison T, Favari E, Borgese L, Shafii M, Gozzer M, Pacella E, Torromeo C, Parassassi T, Berni A, Guardamagna O, Zenti MG, Guitarrini MR, Berretti D, Hohenstein B, Saheb S, Bjelakovic B, Williams H, De Luca N. Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs. *J Clin Lipidol*. 2017;11(4):858–871.e3. doi: [10.1016/j.jacl.2017.04.114](https://doi.org/10.1016/j.jacl.2017.04.114).
- [19] Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol*. 2019;13(3):374–392. doi: [10.1016/j.jacl.2019.04.010](https://doi.org/10.1016/j.jacl.2019.04.010).
- [20] Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): Impact by ethnicity and environmental and medical conditions. *J Lipid Res*. 2016;57(7):1111–1125. doi: [10.1194/jlr.R051904](https://doi.org/10.1194/jlr.R051904).
- [21] Reyes-Soffer G. The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk. *Curr Opin Lipidol*. 2021;32(3). https://journals.lww.com/co-lipidology/Fulltext/2021/06000/The_impact_of_race_and_ethnicity_on_lipoprotein_a_3.aspx.
- [22] Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. *J Am Coll Cardiol*. 2022;80(9):934–946. doi: [10.1016/j.jacc.2022.06.019](https://doi.org/10.1016/j.jacc.2022.06.019).
- [23] Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, ur RMemonF, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. *Lancet Diabetes Endocrinol*. 2017;5(7):524–533. doi: [10.1016/S2213-8587\(17\)30088-8](https://doi.org/10.1016/S2213-8587(17)30088-8).
- [24] Sadiq F, Shafi S, Sikonja J, Khan M, Ain Q, Khan MI, Rehman H, Mlinaric M, Gidding SS, Groselj U, Alam J, Ali M, Anwer J, Awan WA, Bham SQ, Fatima N, Gul F, Hameed SS, Haroon M, Hasan M, Jadoon A, Jamil S, Khan AA, Khan SA, Kidwai SS, Munir A, Bin Nazir MT, Khan Niazi GZ, Qabulio SN, Rana MA, Safdar SRehmanAur, Shah S, Rehman Ahmed Sheikh TU, Yousuf A, Zehra K, Zehra T. Mapping of familial hypercholesterolemia and dyslipidemias basic management infrastructure in Pakistan: A cross-sectional study. *The Lancet Regional Health - Southeast Asia*. 2023;0(0):100163 doi: [10.1016/j.lansea.2023.100163](https://doi.org/10.1016/j.lansea.2023.100163).

- [25] Hanif S, Akhtar B, Afzal MN. Serum lipoprotein (A) levels in acute coronary syndrome; comparison of younger and elderly patients with healthy controls. *Pak J Med Sci.* 2019;35(6):1718–1723. doi: [10.12669/pjms.35.6.377](https://doi.org/10.12669/pjms.35.6.377).
- [26] Habib SS, Aslam M. Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2004;6(5):338–343. doi: <https://doi.org/10.1111/j.1462-8902.2004.00352.x>.
- [27] Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families. *J Lipid Res.* 2019;60(9):1603–1609. doi: [10.1194/jlr.P091249](https://doi.org/10.1194/jlr.P091249).
- [28] Mehta A, Jain V, Saeed A, Saseen JJ, Gulati M, Ballantyne CM, Virani SS. Lipoprotein(a) and ethnicities. *Atherosclerosis.* 2022;349:42–52. doi: [10.1016/j.atherosclerosis.2022.04.005](https://doi.org/10.1016/j.atherosclerosis.2022.04.005).
- [29] Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. *Atherosclerosis.* 2022;349:17–35. doi: [10.1016/j.ATHEROSCLEROSIS.2022.04.003](https://doi.org/10.1016/j.ATHEROSCLEROSIS.2022.04.003).
- [30] Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. *Circulation.* 2019;139(12):1472–1482. doi: [10.1161/CIRCULATIONAHA.118.034311](https://doi.org/10.1161/CIRCULATIONAHA.118.034311).
- [31] Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, Landmesser U, Blaha M, Lincoff AM, Morishita R, Tsimikas S, Liu J, Manning B, Kozlovski P, Lesogor A, Thuren T, Shibasaki T, Matei F, Silveira FS, Meunch A, Bada A, Vijan V, Bruun NE, Nordestgaard BG. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. *Open Heart.* 2022;9(2). doi: [10.1136/openhrt-2022-002060](https://doi.org/10.1136/openhrt-2022-002060).
- [32] Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. *Circulation.* 1986;74(4):758–765. doi: [10.1161/01.CIR.74.4.758](https://doi.org/10.1161/01.CIR.74.4.758).
- [33] Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. *Arterioscler Thromb Vasc Biol.* 2016;36(11):2239–2245. doi: [10.1161/ATVBAHA.116.308011](https://doi.org/10.1161/ATVBAHA.116.308011).
- [34] Nicholls SJ, Tang WHW, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. *J Lipid Res.* 2010;51(10):3055–3061. doi: <https://doi.org/10.1194/jlr.M008961>.
- [35] Safa O, Werba José P, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G. Plasma triglycerides and lipoprotein(a): Inverse relationship in a hyperlipidemic Italian population. *Atherosclerosis.* 1993;101(2):203–211. doi: [10.1016/0021-9150\(93\)90117-D](https://doi.org/10.1016/0021-9150(93)90117-D).
- [36] Bartens W, Rader DJ, Talley G, Brewer Jr HB. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. *Atherosclerosis.* 1994;108(2):149–157. doi: [10.1016/0021-9150\(94\)90109-0](https://doi.org/10.1016/0021-9150(94)90109-0).
- [37] Konerman M, Kulkarni K, Toth PP, Jones SR. Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism. *J Clin Lipidol.* 2012;6(1):27–32. doi: [10.1016/j.jacl.2011.08.004](https://doi.org/10.1016/j.jacl.2011.08.004).
- [38] McConathy WJ, Trieu VN, Koren E, Wang CS, Corder CC. Triglyceride-rich lipoprotein interactions with Lp(a). *Chem Phys Lipids.* 1994;67-68:105–113. doi: [10.1016/0009-3084\(94\)90129-5](https://doi.org/10.1016/0009-3084(94)90129-5).
- [39] Kronenberg F. Lipoprotein(a): From Causality to Treatment. *Curr Atheroscler Rep.* 2024;26(3):75–82. doi: [10.1007/s11883-024-01187-6](https://doi.org/10.1007/s11883-024-01187-6).
- [40] Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. *Eur Heart J.* 2020;41(24):2275–2284. doi: [10.1093/EURHEARTJ/EHZ310](https://doi.org/10.1093/EURHEARTJ/EHZ310).
- [41] De Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, Zwinderman AH, Hutten BA. Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis. *Eur J Prev Cardiol.* 2022;29(5):779–792.
- [42] O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im KA, Pineda AL, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. *Circulation.* 2019;139(12):1483–1492. doi: [10.1161/CIRCULATIONAHA.118.037184](https://doi.org/10.1161/CIRCULATIONAHA.118.037184).
- [43] Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, Reyes-Soffer G. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. *J Lipid Res.* 2018;59(12):2397–2402. doi: [10.1194/jlr.P082834](https://doi.org/10.1194/jlr.P082834).
- [44] Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): A randomized dose-ascending clinical trial. *JAMA.* 2023;330(21):2075–2083. doi: [10.1001/JAMA.2023.21835](https://doi.org/10.1001/JAMA.2023.21835).
- [45] Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. *JAMA.* 2022;327(17):1679–1687. doi: [10.1001/JAMA.2022.5050](https://doi.org/10.1001/JAMA.2022.5050).
- [46] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL. Lipoprotein(a) reduction in persons with cardiovascular disease. *New England Journal of Medicine.* 2020;382(3):244–255. doi: [10.1056/NEJM1905239/SUPPL_FILE/NEJM1905239_DATA-SHARING.PDF](https://doi.org/10.1056/NEJM1905239/SUPPL_FILE/NEJM1905239_DATA-SHARING.PDF).

- [47] Kelsey MD, Mulder H, Chiswell K, Lampron ZM, Nilles E, Kulinski JP, Joshi PH, Jones WS, Chamberlain AM, Leucker TM, Hwang W, Milks MW, Paranjape A, Obeid JS, Linton MF, Kent ST, Peterson ED, O'Brien EC, Pagidipati NJ. Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes. *Am J Prev Cardiol.* 2023;14:100478 doi: [10.1016/j.ajpc.2023.100478](https://doi.org/10.1016/j.ajpc.2023.100478).
- [48] Laufs U, Schorr J, Klebs S. Characteristics of patients with a lipoprotein(a) assessment –a health insurance claims database analysis. *Eur Heart J.* 2021;42(Supplement_1):ehab724.2519. doi: [10.1093/eurheartj/ehab724.2519](https://doi.org/10.1093/eurheartj/ehab724.2519).
- [49] Stürzebecher PE, Schorr JJ, Klebs SHG, Laufs U. Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses. *Atherosclerosis.* 2023;367:24–33. doi: [10.1016/j.atherosclerosis.2023.01.014](https://doi.org/10.1016/j.atherosclerosis.2023.01.014).
- [50] Zafir B, Aker A, Saliba W. Lipoprotein(a) testing in clinical practice: Real-life data from a large healthcare provider. *Eur J Prev Cardiol.* 2022;29(14):e331–e333. doi: [10.1093/eurjpc/zwac124](https://doi.org/10.1093/eurjpc/zwac124).